Crystalys Therapeutics
Crystalys Therapeutics raises $205M Series B at $900M valuation
Quick Facts
Crystalys Therapeutics: Series B Funding Round
Crystalys Therapeutics has successfully raised $205M in Series B funding, reaching a valuation of $900M.
Company Overview
Developing novel therapeutics for neurodegenerative diseases
Funding Details
The Series B round was led by Fidelity, with participation from Viking Global.
Company Information
- Headquarters: Boston, MA
- Founded: 2021
- Employees: 110+
- Category: Biotech
Investment
Crystalys Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series B
- Viking Global: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
HorizonStudio Raises $100M Growth to Transform Biotech
HorizonStudio has secured $100M Growth in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
StreamData Raises $15M Seed to Transform Biotech
StreamData has secured $15M Seed in funding to accelerate growth and innovation. Leading artificial intelligence infrastructure enabling scalable ML deployment for businesses...
